Business context and reporting period
Important identity discrepancy: The supplied filing is for Helix Acquisition Corp. II (Nasdaq: HLXB), not Bridgebio Oncology Therapeutics, Inc. It is a Cayman Islands special purpose acquisition company (SPAC), not an operating oncology business. This unaudited Form 10-Q covers the quarter ended March 31, 2024 and was signed May 15, 2024.
Helix was formed to pursue a business combination, with an intended focus on healthcare and healthcare-related industries. It had not commenced operations or identified revenue-generating activity by quarter-end; its principal activity was seeking a target.
Financial performance and position
| Metric | Q1 2024 / March 31, 2024 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None; no operating revenue | None in Q1 2023 |
| Net income | $1.10 million | $0 in Q1 2023 |
| Interest income from Trust Account | $1.21 million | $0 in Q1 2023 |
| General and administrative expense | $66,701 | $0 in Q1 2023 |
| Share-based compensation expense | $39,372 | $0 in Q1 2023 |
| Cash used in operating activities | $617,999 | $0 in Q1 2023 |
| Cash and cash equivalents | $1.84 million | $0 at December 31, 2023 |
| Trust Account investments | $185.21 million | $0 at December 31, 2023 |
| Total liabilities | $5.54 million, including $5.52 million deferred underwriting fee | $396,463 at December 31, 2023 |
| Shareholders’ deficit | $3.22 million | $63,569 at December 31, 2023 |
Net income reflected Trust Account interest, partly offset by operating and share-based compensation expenses. Operating margins are not meaningful because the company has no operating revenue. The filing reports no long-term debt; a $70,095 related-party promissory note outstanding at year-end was repaid during the quarter. The $5.52 million deferred underwriting fee is payable only if a business combination closes. No cash-flow margin or separate liquidity ratio is provided.
Material changes versus the prior comparable period
- Helix completed its initial public offering on February 13, 2024, selling 18.4 million public shares at $10 each for $184 million gross proceeds, including full exercise of the underwriter’s over-allotment option.
- The Sponsor concurrently purchased 509,000 private placement shares for $5.09 million. The company placed $184 million in the Trust Account; by quarter-end, the account held $185.21 million, including investment income.
- Q1 2024 results therefore include Trust Account interest and public-company expenses; Q1 2023 had no income, expenses, or operating cash flow reported.
- Redeemable Class A shares are presented outside permanent equity at $185.21 million, or $10.07 per share, at March 31, 2024. This contributed to the reported shareholders’ deficit.
Outlook, risks, contingencies, and unusual items
- The company has 24 months from the February 13, 2024 IPO closing to complete a business combination, unless the period is amended. If it does not, it must redeem public shares, subject to applicable requirements.
- Management expects continued costs pursuing an acquisition and says outside-trust funds are expected to cover allocated pre-combination costs, but warns that actual search, diligence, or negotiation costs could exceed estimates. Additional financing may be needed to complete a transaction or address significant redemptions.
- Trust funds are intended primarily for a business combination. Public shareholders may redeem shares in connection with a transaction; the deferred underwriting fee is payable upon a completed transaction.
- The filing reports no material change to IPO-prospectus risk factors, no legal proceedings, no off-balance-sheet arrangements, and no subsequent event requiring adjustment or disclosure. Disclosure controls were assessed as effective at a reasonable-assurance level.
- The filing contains no specific transaction target, transaction guidance, or operating forecast. Results are not indicative of future periods.
Important facts for investors to verify
- Confirm the intended issuer: this filing identifies Helix Acquisition Corp. II, not Bridgebio Oncology Therapeutics, Inc.
- Check for later filings or announcements on a target, proposed business combination, extensions, redemptions, or liquidation deadline.
- Verify Trust Account assets, accrued expenses, and cash available outside the Trust Account, as well as expected acquisition and compliance costs.
- Review the IPO prospectus for redemption terms, founder-share conversion and lockup provisions, Sponsor indemnification limits, and the deferred underwriting fee.